AVR anteris technologies global corp.

Ann: Admedus Releases Results of HSV-2 Phase IIa Study, page-2

  1. 842 Posts.
    lightbulb Created with Sketch. 186
    I don't know much abotu this stuff, but my impression is it isn't looking that good. "The study found that there was a statistically significant 52% reduction in viral shedding rate for vaccine recipients, when the post-vaccine period was compared with pre-vaccine, and a non-significant 31% reduction in shedding was observed over the course of the study for the subjects receiving placebo. When the extent of reduction in shedding was compared between the vaccine and the placebo groups, however, the reduction associated with vaccine was non-significant."
    Last edited by Dazaau: 04/05/17
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
$5.91
Change
0.290(5.16%)
Mkt cap ! $91.59M
Open High Low Value Volume
$5.79 $6.19 $5.79 $17.15K 2.906K

Buyers (Bids)

No. Vol. Price($)
1 38 $5.90
 

Sellers (Offers)

Price($) Vol. No.
$6.10 170 1
View Market Depth
Last trade - 16.10pm 04/07/2025 (20 minute delay) ?
AVR (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.